Based on success in hematological and oncology settings, several IL-6 antagonists (tocilizumab, sarilumab as well as siltuximab) have been utilized as emergency interventions in COVID-19 patients with ARDS and hypotension, although so far with mixed results (148). This evidence concerns the gene IL6 and COVID-19.